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Abstract
Background: Cognitive impairment has been reported in human immune deficiency virus-1- (HIV-1-) infected
patients as well as in HIV-1 transgenic (Tg) rats. This impairment has been linked to neuroinflammation, disturbed
brain arachidonic acid (AA) metabolism, and synapto-dendritic injury. We recently reported upregulated brain AA
metabolism in 7- to 9-month-old HIV-1 Tg rats. We hypothesized that these HIV-1 Tg rats also would show
upregulated brain inflammatory and AA cascade markers and a deficit of synaptic proteins.
Methods: We measured protein and mRNA levels of markers of neuroinflammation and the AA cascade, as well as
pro-apoptotic factors and synaptic proteins, in brains from 7- to 9-month-old HIV-1 Tg and control rats.
Results: Compared with control brain, HIV-1 Tg rat brain showed immunoreactivity to glycoprotein 120 and tat
HIV-1 viral proteins, and significantly higher protein and mRNA levels of (1) the inflammatory cytokines interleukin-
1b and tumor necrosis factor a, (2) the activated microglial/macrophage marker CD11b, (3) AA cascade enzymes:
AA-selective Ca
2+-dependent cytosolic phospholipase A2 (cPLA2)-IVA, secretory sPLA2-IIA, cyclooxygenase (COX)-2,
membrane prostaglandin E2 synthase, 5-lipoxygenase (LOX) and 15-LOX, cytochrome p450 epoxygenase, and (4)
transcription factor NF-Bp50 DNA binding activity. HIV-1 Tg rat brain also exhibited signs of cell injury, including
significantly decreased levels of brain-derived neurotrophic factor (BDNF) and drebrin, a marker of post-synaptic
excitatory dendritic spines. Expression of Ca
2+-independent iPLA2-VIA and COX-1 was unchanged.
Conclusions: HIV-1 Tg rats show elevated brain markers of neuroinflammation and AA metabolism, with a deficit
in several synaptic proteins. These changes are associated with viral proteins and may contribute to cognitive
impairment. The HIV-1 Tg rat may be a useful model for understanding progression and treatment of cognitive
impairment in HIV-1 patients.
Background
Despite improved survival rates for human immunodefi-
ciency virus (HIV-1)-infected patients due to antiretro-
viral therapy, HIV-1-associated neurocognitive disorders
remain a significant public health burden [1,2]. Among
HIV-1-infected patients, cognitive impairment is a ser-
ious complication of HIV-1-infection, and occurs in a
substantial (15-50%) proportion of patients [2]. Indeed,
a pilot study revealed high rates of asymptomatic
neurocognitive impairment in perinatally infected HIV-
positive young adults (67%) when compared with older
subjects (19%) [3]. Another study highlighted that the
prevalence of HIV-associated neurocognitive disorders is
high even among long-standing aviremic HIV-positive
patients [4].
Deficits in spatial learning also have been demon-
strated in aged HIV-1 transgenic (Tg) rats [5,6]. The
HIV-Tg rat contains the HIV-1 virus in its genome, but
is not infectious because it lacks the gag and pol replica-
t i o ng e n e so ft h ev i r u s[ 7 ] .H I V - 1T gr a t se x p r e s st h e
functional viral envelope proteins glycoprotein (gp) 120
and trans-activator of transcription (Tat) in brain and
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these rats can be used to examine effects of these envel-
ope proteins in the absence of infection (viral replica-
tion), which may mimic the condition in patients given
highly active antiretroviral therapy, who have limited
(controlled) viral replication but persistent HIV-1 infec-
tion [8]. HIV-1 Tg rats demonstrate reduced spatial
l e a r n i n ga t5m o n t h so fa g e ,a n db y7 - 9m o n t h ss h o w
neuroinflammation and upregulated brain arachidonic
acid (AA) metabolic rates [5,6,9].
Synapto-dendritic injury, a likely cause of cognitive
impairment in HIV-1 patients [10-12], can be exacer-
bated by a neuroinflammatory microenvironment [13].
During inflammation, AA is released from membrane
phospholipids by AA-selective Ca
2+-dependent cytosolic
phospholipase A2 (cPLA2) and secretory sPLA2.T h i s
process is associated with increased production of cyto-
kines (e.g., tumor necrosis factor alpha (TNFa)a n d
interleukin (IL)-1b and nitric oxide from activated
microglia. Released TNFa and IL-1b can continue to
activate AA cascade metabolism by activating transcrip-
tion factor NF-B [14-17]. Further, the released AA can
be converted into pro-inflammatory lipid mediators,
such as prostaglandin (PG) H2, leukotrienes, and related
compounds by the action of cyclooxygenase (COX),
lipoxygenase (LOX) and thromboxane synthase (TXS)
enzymes. PGH2 is converted to PGE2 by membrane
prostaglandin E synthase (mPGES) or cytosolic PGES
(cPGES), or by TXS to TXA2. HIV-1 patients show
increased concentrations of PGE2,P G F 2 and TXB2 in
their cerebrospinal fluid [18], consistent with in vivo
and in vitro studies [19-21].
A relation of AA and its pro-inflammatory metabolites
to neuronal apoptosis and synapse loss has been demon-
strated in vivo and in vitro [22-26]. Furthermore,
reduced dendritic spine density and complexity have
been associated with deficits in learning, memory, and
general cognitive function [12]. Neuronal loss also may
result from insufficient trophic factors, including brain-
derived neurotrophic factor (BDNF) [27]. The post-
synaptic dendritic proteins, drebrin and neurofilament
light chain (L), are abundantly expressed in neurons
[28-31], and changes in their expression have been used
to evaluate neuronal damage [32,33]. Loss of drebrin
has been associated with cognitive impairment in Alz-
heimer disease and mild cognitive impairment patients
[32,34-37]. However, an association between synapse
loss and upregulation of the AA cascade has not been
identified in vivo. In the current study we used 7- to 9-
month-old HIV-1 Tg rats to characterize the brain pro-
inflammatory microenvironment and synaptic integrity
(determined by levels of drebrin and neurofilament-L).
We now show upregulated levels of AA cascade markers
and of IL-1b and TNFa in the brain of these HIV-1 Tg
rats, in association with lower levels of BDNF, drebrin
and neurofilament-L.
Methods
Animals
This protocol was approved by the Animal Care and
Use Committee of the Eunice Kennedy Shriver National
Institute of Child Health and Human Development, and
followed the National Institutes of Health Guide for the
Care and Use of Laboratory Animals (NIH Publication
86-23). Seven- to 9-month-old male, specific pathogen-
free, Fischer 344/Hsd HIV-1 Tg rats (n = 6) and age-
matched parental wild-type inbred Fischer 344/Hsd
non-Tg control rats (n = 6) were purchased from Harlan
Laboratories (Indianapolis, IN) and housed in an animal
facility with controlled temperature, humidity, and 12-h
light/dark cycle. Food (Teklad global 18% protein diet,
2018S (sterilized) for controls and 2918 (irradiated) for
HIV-1 Tg rats (Harlan) [9] and water were provided ad
libitum. After three days of acclimation, rats were anaes-
thetized with an overdose of CO2 and decapitated. Their
brain was rapidly excised, sagittally cut into four sec-
tions from the left and right hemispheres, frozen in 2-
methylbutane at -50°C, and stored at -80°C until stu-
died. One section from the left hemisphere from each
rat was used to isolate the cytosolic fraction, a corre-
sponding section from the right hemisphere was used
for total RNA extraction, and remaining sections from
both hemispheres were used to prepare nuclear extracts.
Preparation of cytosolic fractions
Cytosolic brain fractions were prepared as reported [38].
One section from each brain was homogenized in a buf-
fer containing 20 mM Tris-HCl (pH 7.4), 2 mM EGTA,
5m ME D T A ,1 . 5m Mp e p s t a t i n ,2m Ml e u p e p t i n ,0 . 5
mM phenylmethylsulfonyl fluoride, 0.2 U/ml aprotinin,
and 2 mM dithiothreitol, using a Polytron homogenizer.
The homogenate was centrifuged at 100,000 g for 60
min at 4°C, and the resulting supernatant (cytosolic frac-
tion) collected. Protein concentrations were determined
using Bio-Rad Protein Reagent (Bio-Rad, Hercules, CA).
Total RNA isolation and real time RT-PCR
Brain tissue was homogenized in Qiagen
® lysis solution
and total RNA was isolated by phenol-chloroform
extraction using a RNeasy
® lipid tissue mini kit (Qiagen,
Valencia, CA). Complementary DNA was prepared from
total RNA using a high-capacity cDNA Archive kit
(Applied Biosystems, Foster City, CA). mRNA levels (IL-
1b,T N F a,G F A P ,C D 1 1 b ,c P L A 2-IVA, sPLA2-IIA,
iPLA2-VIA, COX-1, COX-2, mPGES, cPGES, 5-, 12-,
1 5 - L O X ,T X S ,c y t o c h r o m ep 4 5 0e p o x y g e n a s e ,d r e b r i n
and neurofilament-L) were measured by quantitative
RT-PCR, using an ABI PRISM 7000 sequence detection
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probes for cPLA2-IVA B,s P L A 2-IIA B,i P L A 2-VIA,
COX-1, COX-2, mPGES, cPGES, 5-, 12-, 15-LOX, TXS,
cytochrome p450 epoxygenase, drebrin and neurofila-
ment-L were purchased from TaqMan
R gene expression
assays (Applied Biosystems), and consisted of a 20× mix
of unlabeled PCR primers and Taqman minor groove
binder (MGB) probe (FAM dye-labeled). The fold-
change in gene expression was determined by the ΔΔCT
method [39]. Data are expressed as the relative level of
the target gene (IL-1b,T N F a, GFAP, CD11b, cPLA2-
IVA B, sPLA2-IIA, iPLA2-VIA, COX-1, COX-2, mPGES,
cPGES, 5-, 12-, and 15-LOX, TXS, cytochrome p450
epoxygenase, drebrin or neurofilament-L) in the brain of
the HIV-1 Tg rat normalized to the endogenous control
(b-globulin) and relative to the control (calibrator). All
experiments were carried out in triplicate from each
control and HIV-1 Tg rat brain (n = 6).
Western blot for protein levels
Proteins from the cytosolic fraction (65 μg) were sepa-
rated on 4-20% SDS-polyacrylamide gels (PAGE) (Bio-
Rad), and electrophoretically transferred to a nitrocellu-
lose membrane (Bio-Rad). Cytosolic protein blots were
incubated overnight in Tris-buffered-saline containing
5% nonfat dried milk and 0.1% Tween-20, with specific
primary antibodies for proinflammatory cytokines: IL-1b
(1:500), TNFa (1:500); astrocytes: glial fibrillary acidic
protein (GFAP) (1:1000); CD11b (1:1000); AA cascade
proteins: cPLA2-IVA, sPLA2-IIA, iPLA2-VIA, COX-1
(1:1000), COX-2 (1:1000), cytochrome p450 epoxygen-
ase, TXS, 5-, 12-, 15-LOX, mPGES, cPGES (1:1000);
gp120 (1:100); tat (1:100); drebrin (1:1000), BDNF
(1:1000) (Santa Cruz, Santa Cruz, CA);); neurofilament-
L (1:500) (Cell Signaling Technology, Danvers, MA) and
b-actin (1:10,000) (Sigma Aldrich, St. Louis, MO). The
cytosolic blots were incubated with appropriate horse-
radish peroxidase (HRP)-conjugated secondary antibo-
dies (Bio-Rad), and were visualized using a
chemiluminescence reaction (Amersham, Piscataway,
NJ). Optical densities of immunoblot bands were mea-
sured using Alpha Innotech Software (Alpha Innotech,
San Leandro, CA) and were normalized to b-actin. All
experiments were conducted on 6 independent samples.
Values are expressed as percent of control.
Transcription factor NF-Bp50 and NF-Bp65 activities
Nuclear extracts were prepared as reported [40,41] and
protein concentrations were determined using Bio-Rad
Protein Reagent (Bio-Rad). NF-Bp50 and NF-Bp65
activities were measured according to the manufac-
turer’s instructions (Panomics, Freemont, CA), using
nuclear extracts obtained from the control and HIV-1
Tg rats. Briefly, 10 μg of nuclear extract from each
sample was preincubated with biotin-labeled NF-Bp50
or p65 oligonucleotides in a separate vial for 60 min.
The labeled oligonucleotide-nuclear protein complexes
were immobilized on a streptavidin-coated 96-well plate.
The bound oligonucleotide nuclear protein complex was
detected by adding NF-Bp50 or p65 antibody to the
respective NF-Bp50 or p65 complex, followed by addi-
tion of secondary antibody conjugated to HRP. Color
was developed with tetramethylbenzidine substrate and
optical densities were measured at 450 nm. Values are
expressed as percent of control. All experiments were
conducted on 6 independent samples.
Measurement of active caspase-3 protein
Active caspase-3 protein was measured according to the
manufacturer’s instructions (Cell Signaling, Danvers,
MA), using cytosolic brain fractions from the control
and HIV-1 Tg rats Briefly, 100 μl( 1 0 0μg) of cytosolic
fraction was incubated with pre-coated capture antibody
in a microwell plate overnight at 4°C. After incubation,
the target protein was captured by coated antibody. Fol-
lowing extensive washing, an HRP-linked secondary
antibody was added to recognize the bound antibody
complex. Color was developed with tetramethylbenzi-
dine substrate and optical densities were measured at
450 nm. Values are expressed as percent of control. All
experiments were conducted on 6 independent samples.
Immunohistochemistry
In a separate cohort of animals, astrocyte and microglia
morphology was analyzed by immunohistochemistry.
Following CO2 anesthesia, the brain (n = 4) was rapidly
excised, cut in the midsagittal plane, and the individual
hemispheres immersion-fixed in 4% paraformaldehyde/
phosphate buffer (pH 7.2) for 18 h, followed by cryopro-
tection. Fifty- μm free-floating coronal serial cryosec-
tions of the forebrain were stored in solution (FD
Neurotechnologies, Baltimore, MD) at -20°C. Sections
(between +1.0 and 0.4 mm from bregma) were washed
with phosphate buffered saline (PBS), equilibrated to
room temperature (RT), transferred to 10 mM citrate
buffer containing 0.05% Tween-20 and incubated 30
min at 80°C. Sections were then rinsed in PBS and incu-
bated 2 h in blocking solution (2% goat serum, 1%
bovine serum albumin, 0.1% Triton X-100 in automa-
tion buffer (Biomedia, Foster City, CA). Sections were
incubated with anti-GFAP or ionized calcium binding
adopter molecule 1 (Iba-1, 1:500, Dako, Glostrup, Den-
mark) in blocking solution for 18 h at 4°C, re-equili-
brated to RT, washed with PBS, and incubated with
Alexa Fluor antibody conjugates (1:250, Invitrogen,
Carlsbad, CA) in blocking solution without Triton X-
100 for 2 h at RT. Digital images of immunostaining in
the somatosensory cortex and the dentate gyrus of the
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confocal laser-scanning microscope (Carl Zeiss, Oberko-
chen, Germany) equipped with argon, HeNe, and iFlex
2000 PSU lasers. Image stacks were collected at 1.5 mm
steps (20×) or 1.0 mm steps (63×) and displayed as a
single image using 3D maximum projection.
Statistics
Data are expressed as mean ± SEM. We used t-tests for
independent samples for group comparisons. We further
tested significance using the false discovery rate (FDR)
to correct for multiple comparisons. We set alpha =
0.01 to reduce type one error risk. An alpha = 0.01 and
an n of 15 markers per mRNA and protein assays would
give a 14% chance of at least one false positive for each
mRNA and protein assay using the following formula 1-
(1-.01)e
15. A p value less than 0.01 and 0.001 is repre-
sented by ** and *** respectively.
Results
Gp120 and tat proteins and neuroinflammatory markers
in HIV-1 Tg rats
Gp120 and tat protein levels were detectable in cytosolic
brain fractions of HIV-1 Tg but not of control rats (Fig-
ure 1A). Brain mRNA and protein levels for the astro-
cyte structural protein, GFAP, were not significantly
altered in the HIV-1 Tg rats compared to controls (Fig-
ure 1B-C). As a molecular marker for activated
microglia and macrophages [42], mRNA level of the
CD11b was elevated significantly by 7.1-fold in the HIV-
1 Tg compared with control brain (Figure 1D), corre-
sponding to a significant 190% elevation in CD11b pro-
tein (Figure 1E) (p < 0.001).
To characterize regional specificity of the changes, we
measured GFAP immunoreactivity and microglial mar-
kers in the hippocampus and somatosensory cortex. In
contrast to the initial report on the HIV-1 Tg rat [7],
histological examination of the somatosensory cortex
(Figures 2 A-B) and of the hippocampus (Figures 2 C-
D) did not indicate increased GFAP immunoreactivity in
the HIV-1 Tg rats, as their cells maintained a normal
thin process-bearing morphology and there was no evi-
dence of astrocyte hypertrophy (Figures 2 E-H). When
we examined the morphological phenotype of microglia
within various brain regions using Iba-1+ to label
diverse phenotypes, minimal differences from control
were noted in the HIV-1 Tg rats (Figures 3 A-H). In the
somatosensory cortex, microglia maintained a normal
appearance with fine ramified processes and had no pro-
minent evidence of activation or of a phagocytic pheno-
type (Figures 3 A-B). When these immunopositive cells
were examined at higher magnification (Figures 3 E-F),
the Iba-1+ cells displayed decreased arbor complexity.
Given previous reports of deficits in a hippocampal-
dependent spatial memory task in HIV-1 Tg rats, we
further examined the morphological phenotype of
microglia within the dentate gyrus of the hippocampus.
Overall labeling of Iba-1+ microglia was not significantly
different in the HIV-1 Tg compared to control rats, with
no evidence of overt microglia activation or amoeboid
phenotype (Figures 3 C-D). At higher magnification,
Iba-1+ microglia displayed fine processes and compli-
cated arborization in the control brain (Figure 3G). A
distinct difference was noted in the Iba-1+ microglia in
the HIV-1 Tg rat hippocampus, with the cells displaying
diminished arbor complexity and approximately 50%
shortened processes (p < 0.05 by t-test) as determined
by a modified Sholl analysis (Figure 3H), but with no
evidence of amoeboid phagocytic microglia.
Increased proinflammatory cytokine response in HIV-1Tg
brains
HIV-1 Tg rats showed significantly increased mRNA
levels of inflammatory cytokines IL-1b (9.6-fold) (p <
0.001) and TNFa (3.5-fold) (p < 0.01) respectively (Fig-
ures 4A, B). These elevations corresponded to elevated
brain protein levels of IL-1b (59%) and TNFa (45%) as
compared to controls (Figures 4C, D) (p < 0.01). There
was a 73% increase in NF-Bp50 activity in HIV-1 Tg
compared to control rat brain (Figure 4E) (p < 0.01).
However, NF-Bp65 activity did not differ significantly
between groups (Figure 4F).
Figure 1 (A) Representative immunoblot of gp120 and tat
protein in HIV-1 Tg rat brain (A), detected as described in
Methods. mRNA levels of brain GFAP (B) and CD11b (D) in control
and HIV-1 Tg rat brain, measured using real time RT-PCR, normalized
to b-globulin and relative to control level (calibrator) using the ΔΔCT
method. Representative immunoblots of (C) GFAP and (E) CD11b
protein in control and HIV-1 Tg rat brain. Bar graphs are ratios of
optical densities of individual protein bands to b-actin, expressed as
percent of control. Data represent mean ± SEM, statistical
significance: **p < 0.01, ***p < 0.001 as determined by unpaired t-
test.
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rat brain
Brain protein and mRNA levels of a number of AA cas-
cade markers were elevated significantly in HIV-1 Tg
rats relative to controls. Mean mRNA levels of cPLA2-
IVA, sPLA2-IIA and COX-2 were increased (p < 0.01) in
HIV-1 Tg compared to control rats by 5-fold, 9-fold and
Figure 2 Representative immunofluorescence (gray scale) for
GFAP+ astrocytes (white) in layers IV-V of somatosensory
cortex of control (A) and HIV-1 Tg rats (B) and in the
hippocampus dentate gyrus of control (C) and HIV-1 Tg rats
(D) at 7 months of age. Scale bar = 50 microns. In 3-5 sections
obtained from each of 4 animals per group, there was no evidence
of astrocyte hypertrophy as represented in the higher magnification
image of the astrocyte morphology in the (E, F) somatosensory
cortex or (G, H) hippocampus. Images represent compiled z-stack
images collected through a 50 micron section. Scale bar = 4
microns.
Figure 3 Representative immunofluorescence (gray scale) for
Iba-1+ microglia (white) in layers IV-V of the somatosensory
cortex of control (A, C) and HIV-1 Tg rats (B, D) and within the
dentate gyrus of the hippocampus of control (E, G) and HIV-1
Tg (F, H) rats at 7 months of age. Images represent compiled z-
stack images collected throughout a 50 micron section. Higher
magnification of individual representative cells demonstrates
diminished arborization of Iba-1+ microglia primarily within the
hippocampus. Microglia within defined regional areas were
randomly selected (10/section/animal) and the projection distance
of the processes was determined using a modified Sholl analysis. In
the control brain, 90% (± 10%) of the processes projected past the
4
th Sholl while in the HIV-1 Tg rat this was decreased to only 40%
(± 18%). Estimates of complexity of the dendritic branching were
generated by counting the number of processes originating at cell
body. The number of processes was not statistically different from
the number in the HIV-1 Tg rat hippocampus, ranging between 5
and 6 in Tg rats and between 7 and 8 in controls, although
complexity and secondary branching appeared lower.
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mRNA level did not differ between groups (HIV-1 Tg
0.92 ± 0.12 vs. control 1.00 ± 0.30). Mean mRNA levels
of mPGES (Figure 5D), COX-1 (HIV-1 Tg 0.87 ± 0.20
vs. control 1.00 ± 0.20) and cPGES (HIV-1 Tg 0.97 ±
0.20 vs. control 1.00 ± 0.20) were not significantly differ-
ent between groups.
The mean protein level of cPLA2-VIA was increased
by 119% (p < 0.01), whereas sPLA2 IIA protein was not
changed significantly, as the increase was only at p <
0.05 (Figures 5E, F). The mean iPLA2--VIA protein level
also did not differ significantly between groups (HIV-1
Tg 114 ± 6.8 vs. control 100 ± 15). The mean protein
level of COX-2 was increased significantly by 42% (p <
0.01) (Figure 5G), but the mean mPGES protein level
was not (Figure 5H). COX-1 and cPGES protein levels
did not differ significantly between groups (COX-1,
HIV-1 Tg 118 ± 17 vs. control 100 ± 15; cPGES, HIV-1
Tg 101 ± 11.2 vs. control 100 ± 11).
5-LOX, 15-LOX and p450 epoxygenase expression in HIV-
1 Tg rat brain
There were statistically significant increases in mean
brain mRNA levels of 5-LOX, 15-LOX and cytochrome
p450 expoxygenase in HIV-1 Tg relative to control rats
by 2.9-fold (Figure 6A) (p < 0.001), 4.6-fold (Figure 6B)
(p < 0.01) and 4.4-fold (Figure 6C), respectively. Upregu-
lation of these was unaccompanied by significant eleva-
tions in the respective mean protein levels, whose
increases in each case were only at p < 0.05 (Figures
6D-F). Further, there was no significant difference in 12-
LOX or TXS protein between groups (data not shown).
Figure 4 mRNA levels of brain IL-1b (A) and TNFa (B) in control and HIV-1 Tg rats, measured using real time RT-PCR. Data are levels of
brain IL-1b and TNFa in the HIV-1 Tg rat normalized to b-globulin and represented relative to control level (calibrator) using the ΔΔCT method.
Representative immunoblots of (C) IL-1b and (D) TNFa protein in control and HIV-1 Tg rat brain. Bar graphs are ratios of optical densities of
immunoblots to b-actin, expressed as percent of control (mean ± SEM). Representative brain transcription factor binding activities (DNA-protein
complex) of NF-Bp50 (E) and NF-Bp65 (F) in control and HIV-1 Tg rats. DNA binding activity was measured in brain nuclear extracts as
described in Methods. Data represent mean ± SEM. Statistical significance: **p < 0.01, ***p < 0.001 as determined by unpaired t-test.
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The active caspase 3 protein level (Figure 7A), and levels
of neurofilament-L mRNA and protein (Figures 7C, D)
did not differ significantly between HIV-1 Tg and con-
trol rats, as the former mean decreased at p < 0.05 and
the values for neurofilament-L increased only at p <
0.05. BDNF protein (Figure 7B) and drebrin mRNA and
protein (Figures 7E, F) were significantly less in HIV Tg
than control rats (p < 0.01).
Discussion
Direct effects of viral gp120 and tat proteins or second-
ary effects due to neuroinflammatory factors have been
associated with HIV-1 infection and HIV-1 related cog-
nitive impairment. HIV-1 Tg rats aged 7-9 months
showed gp120 and tat protein in brain, accompanied by
significantly elevated AA cascade markers. These differ-
ences were accompanied by significant (p < 0.01) eleva-
tions in mRNA levels of neuroinflammatory cytokines
TNFa and IL-1b,a n do ft h em i c r o g l i a lm a r k e rC D 1 1 b ,
and reductions in mRNA and protein levels for the
synaptic marker, drebrin. These changes occurred in the
absence of significantly increased expression of GFAP
protein, a marker of astrogliosis.
Elevations in the neuroinflammatory and the AA signaling
cascade in HIV-1 Tg rats
We have reported increased cPLA2-IV and sPLA2-IIA
activities in the brain of 7- to 9-month-old HIV-1 Tg
rats [9]. Consistent with these findings, HIV-1 Tg rat
brain in the present study showed elevated protein and
mRNA levels (p < 0.01) of cPLA2-IVA and an elevated
mRNA level of sPLA2-IIA, without a significant change
in iPLA2-VIA or sPLA2-IIA protein levels. COX-2
mRNA and protein levels were significantly higher in
HIV-1 Tg rats than controls, whereas COX-1, cPGES or
TXS did not differ significantly, consistent with our
report of an increased brain concentration of PGE2 but
Figure 5 mRNA levels of brain cPLA2-VIA (A), sPLA2-II (B), COX-2 (C), and mPGES (D) in control and HIV-1 Tg rats, determined using
real time TaqMan RT-PCR. Data are levels of brain cPLA2-VIA, sPLA2-II, COX-2 and mPGES in the HIV-1 Tg rat normalized to the endogenous
control (b-globulin) and relative to control level (calibrator) using the ΔΔCT method. Representative immunoblots of (E) cPLA2-VIA, (F) sPLA2- IIA
(G) COX-2, and (H) mPGES protein in control and HIV-1 Tg rats. Bar graphs represent ratios of optical densities of each individual protein band
relative to b-actin, expressed as percent of control mean ± SEM. Mean ± SEM. Data were analyzed by individual unpaired t-tests, statistical
significance: **p < 0.01, ***p < 0.001.
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and mRNA levels were also were not increased in HIV-
1 Tg rats.
Our earlier study also showed elevated levels of leuko-
triene B4,ap r o d u c to f5 - L O Xa n dl e u k o t r i e n eA 4
hydrolase, in the brain of HIV-1 Tg rats [9]. Consistent
with that report, HIV-1 Tg brain in the present study
showed significantly increased 5-LOX mRNA without a
significant change in 12-LOX expression. This change
was accompanied by increased mRNA levels of cyto-
chrome p450 expoxygenase and 5-LOX. Given that
epoxyeicosatrienoic acid produced by cytochrome p450
expoxygenase can be neuroprotective [43,44], the ele-
vated brain mRNA level of cytochrome p450 epoxygen-
ase in HIV-1 Tg may reflect a compensatory
n e u r o p r o t e c t i v ep r o c e s s .W h i l ee l e v a t i o n si np r o t e i n
levels of 5-LOX, 15-LOX and cytochrome p450 expoxy-
genase did not reach significance because of our
requirement for multiple comparisons, in each case
changes were in the same direction as elevations of the
respective mRNA at p < 0.05.
The changes in the AA cascade markers noted in
HIV-1 Tg rat brain may be related to microglial activa-
tion, with release of proinflammatory cytokines and acti-
vation of the NF-B transcription factor. NF-B binding
sites are present on the promoter region of the gene
transcripts of the AA cascade markers, cPLA2-IVA,
sPLA2-IIA and COX-2 [45-47]. Cell culture studies have
shown that IL-1b or TNFa can induce transcription of
cPLA2, sPLA2 and COX-2 genes in an NF-B-dependent
manner [14-17,48]. NF-Bp50 is known to regulate
transcription of pro-inflammatory genes [49,50] and can
Figure 6 mRNA levels of brain 5-LOX BB(A), 15-LOX (B) and cytochrome p450 epoxygenase (C) in control and HIV-1 Tg rats, measured
using real time TaqMan RT-PCR. Data represent individual transcript levels normalized to b-globulin, in HIV-1 Tg rat brain relative to control
level (calibrator) using the ΔΔCT method. Representative immunoblots of (D) 5-LOX, (E) 15-LOX, and (F) cytochrome p450 epoxygenase protein in
control and HIV-1 Tg rats. Bar graphs display ratios of optical densities of individual protein bands to b-actin, expressed as percent of control.
Mean ± SEM, statistical significance: **p < 0.01, ***p < 0.001 as determined by an unpaired t-test.
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binding activity of NF-Bp50 in the HIV-1 Tg rat sug-
gests that the elevated AA cascade markers in the cur-
rent study may be related to increased levels of IL-1b
and TNFa and increased NF-Bp50 DNA binding activ-
ity, but are independent of NF-Bp65.
In the absence of HIV-1 replication, the presence of
gp120 and tat proteins in HIV-1 Tg rat brain likely
account for microglial activation and the increased level
of CD11b. In vitro, gp120 directly stimulates microglia
and increases expression of CD11b [52]. However,
microglia did show retraction of their processes and
diminished complexity of arborization, which suggests
an early reactive response. As we did not examine ani-
mals younger than 7 months, we cannot conclude that
these changes were age-related. The altered microglial
morphology in the hippocampus is of interest, given the
role of the hippocampus in spatial learning tasks and
the proposed involvement of microglia during synapse
stripping and remodeling [53]. CD11b and Iba-1 cannot
be used to distinguish between resident microglia and
infiltrating blood borne monocytes. Thus, while we did
not observe amoeboid brain macrophages, we cannot
rule out a contribution of monocytes from the circula-
tion, especially since gp120 can compromise the blood-
brain barrier [54].
In vitro, gp120 can stimulate AA release and PGE2
formation in glial cells [19-21] and elevate levels of IL-
1b in co-cultures of primary hippocampal neurons and
astrocytes [19]. In the initial characterization of the
HIV-1 Tg rat, a response of astrocytes was suggested by
an increase in GFAP immunoreactivity [7]. In the cur-
rent study, we did not find an astrocytic response. Con-
sistent with no change in astroglial morphology, protein
Figure 7 (A) Representative brain active caspase-3 level in control and HIV-1 Tg rats. The active caspase-3 level was measured in brain
cytosolic fractions as described in Methods. Bar graphs are relative to control and were compared using an unpaired t-test, mean ± SEM.
Representative immunoblots of BDNF (B), neurofilament-L (D) and drebrin (F) protein levels in control and HIV-1 Tg rats. Bar graphs display mean
± SEM optical densities of individual protein bands relative to b-actin, expressed as percent of control. mRNA levels of neurofilament-L (C) and
drebrin (E) in control and HIV-1 Tg rat brain, measured using real time TaqMan RT-PCR. Data represent mean ± SEM mRNA levels in the HIV-1 Tg
rat brain normalized to b-globulin, relative to control level (calibrator) using the ΔΔCT method. statistical significance: **p < 0.01, ***p < 0.001 as
determined by an unpaired t-test.
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Page 9 of 13and mRNA levels of astroglial marker GFAP were not
significantly altered. Further studies are needed to
understand the role of astrocytes in HIV-1 infection.
Similar to gp120, tat protein is also known to stimulate
AA release and COX-2 expression in rat brain [55-57].
The changes observed with neuroinflammatory and AA
cascade markers in HIV-1Tg rats could be due to the
presence of tat protein in the HIV-1Tg brain. Alto-
gether, viral proteins can induce neuroinflammatory and
AA cascade markers in brain. Despite altered protein
levels of the AA cascade enzymes 5-LOX, 12-LOX and
p450 epoxygenase a p < 0.05 in HIV-1 Tg brain, these
changes did not reach statistical significance at p < 0.01.
This may be due to the small sample size; further stu-
dies are required to understand changes in HIV-1 Tg
brain.
HIV-1 Tg rats show subtle changes in synaptic marker
Neuropathological features of human HIV-1 infection
include cortical atrophy, altered dendritic arborization of
neurons, and decreased synaptic density [10-12,58].
Neurons are vulnerable to both gp120 and the HIV-1
virus protein, tat [59,60]. Gp120 and tat are reported to
induce apoptosis of neurons in vitro and in vivo [61-63]
by activating caspases, particularly caspase-3 [59]. The
current study did not show a statistically significant
increase in the protein level of active caspase-3 in HIV-
1 Tg rats. Damage and apoptosis of neurons would be
manifest as a loss of neuronal and related markers.
Within this framework, we now report a significantly
lower mRNA and protein levels of the post-synaptic
dendritic marker drebrin, and a reduced protein level of
BDNF (p < 0.01). Protein and mRNA levels of neurofila-
ment-L were reduced only at p < 0.05 in the HIV-1 Tg
rats. Reduced BDNF is consistent with a report that
gp120 reduces BDNF in rat brain in association with
neuronal death [59]. A lifelong presence of gp120 in
brain may impair neuronal development by reducing
neurofilament and microtubule expression [32]. A sig-
nificantly reduced level of drebrin suggests that altered
synaptic structure contributes to cognitive-behavioral
defects reported in the HIV-1 Tg rat [5,6].
In brain, microglia are the primary source of TNFa
[64,65], and its release is implicated in neurotoxicity [66].
In HIV-1 Tg rats, elevated levels of IL-1b and TNFa and
increased expression of AA cascade enzymes, have been
implicated in neuronal damage [67] and cognitive-beha-
vioral impairment [68-73]. A recent study indicates that
similar changes could contribute to cognitive impairment
in HIV-1 infected patients despite antiretroviral therapy
[74]. An association of increased expression of AA cas-
cade enzymes with neurocognitive/neurodegeneration
also has been suggested for Alzheimer disease and vascu-
lar dementia [75,76]. In this regard, cPLA2 inhibition or
deletion improved learning and memory performance in
at r a n s g e n i cm o u s em o d e lo fA l z h e i m e rd i s e a s e[ 7 2 ] .
Treatment with lithium or sodium valproate also was
beneficial in HIV-1 associated dementia patients [77,78],
possibly by attenuating neuroinflammation and an upre-
gulated brain AA cascade [79,80]. Collectively, these
observations suggest that neuroinflammation associated
with increased AA metabolism can contribute to cogni-
tive impairment, and that attenuation of AA release by
inhibiting cPLA2 may be beneficial.
The significant changes observed with AA cascade and
neuroinflammation markers in HIV-1 Tg rats must be
interpreted with caution because potential contamina-
tion of brain tissue by peripheral cells during cytosolic
or total RNA isolation would give higher background
levels for measured proteins, except for the neuron-spe-
cific marker drebrin. However, such changes are unlikely
b e c a u s ew ea r e p o r t e di n c r e a sed global brain AA incor-
poration from plasma in awake HIV-1 Tg rats [9].
Further examination is required to study the extent of
activation of neuroinflammation and AA cascade mar-
kers in peripheral cells of HIV-1 Tg rats.
While differences between HIV-1 Tg and controls
rates in several brain measures at the p < 0.05 level
were not considered statistically significant because of
the constraint of multiple comparisons (see Methods),
they should be given some weight for several reasons,
and might be reconsidered in the future with larger
samples. This study was exploratory, and was focused
on generating hypotheses that could be tested more dis-
cretely in the future. Importantly, many of the p < 0.05
changes in a protein occurred with a significant change
at p < 0.01 in the respective mRNA, and vice versa,
making the p < 0.05 change more credible.
Conclusion
Multiple markers of neuroinflammation and the AA cas-
cade are upregulated, and levels of the postsynaptic
markers drebrin and BDNF are reduced, in brain of 7-
to 9-month-old HIV-1 Tg rats compared with control
rats. These changes may contribute to cognitive impair-
ment in these rats, and likely are related to the presence
of viral proteins that trigger activation of several path-
ways. Our study provides additional critical characteriza-
tion of neuropathological changes in the mature HIV-1
Tg rat, further establishing this rat as a potentially use-
ful animal model to examine disease progression and
effects of therapeutic intervention that can impact treat-
ment and understanding of cognitive and behavioral
changes in HIV-1 infected patients.
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